|
US4152413A
(en)
|
1978-08-18 |
1979-05-01 |
Chromalloy American Corporation |
Oral vaccine for swine dysentery and method of use
|
|
US4520019A
(en)
|
1982-04-29 |
1985-05-28 |
Ribi Immunochem Research, Inc. |
Stable composition and preparation thereof
|
|
US4579945A
(en)
|
1982-04-29 |
1986-04-01 |
Ribi Immunochem Research, Inc. |
Purification of trehalose dimycolates
|
|
US4505899A
(en)
|
1982-05-26 |
1985-03-19 |
Ribi Immunochem Research, Inc. |
Refined detoxified endotoxin product
|
|
US4436727A
(en)
|
1982-05-26 |
1984-03-13 |
Ribi Immunochem Research, Inc. |
Refined detoxified endotoxin product
|
|
US4435386A
(en)
|
1982-05-26 |
1984-03-06 |
Ribi Immunochem Research, Inc. |
Refined detoxified endotoxin product
|
|
US4866034A
(en)
|
1982-05-26 |
1989-09-12 |
Ribi Immunochem Research Inc. |
Refined detoxified endotoxin
|
|
US4436728A
(en)
|
1982-05-26 |
1984-03-13 |
Ribi Immunochem Research, Inc. |
Refined detoxified endotoxin product
|
|
US4505900A
(en)
|
1982-05-26 |
1985-03-19 |
Ribi Immunochem Research, Inc. |
Refined detoxified endotoxin product
|
|
US5811128A
(en)
|
1986-10-24 |
1998-09-22 |
Southern Research Institute |
Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor
|
|
US5075109A
(en)
|
1986-10-24 |
1991-12-24 |
Southern Research Institute |
Method of potentiating an immune response
|
|
CA1331443C
(en)
|
1987-05-29 |
1994-08-16 |
Charlotte A. Kensil |
Saponin adjuvant
|
|
US5057540A
(en)
|
1987-05-29 |
1991-10-15 |
Cambridge Biotech Corporation |
Saponin adjuvant
|
|
US4897268A
(en)
|
1987-08-03 |
1990-01-30 |
Southern Research Institute |
Drug delivery system and method of making the same
|
|
WO1993000077A1
(en)
*
|
1991-06-21 |
1993-01-07 |
University Of Cincinnati |
Orally administrable therapeutic proteins and method of making
|
|
EP0678034B1
(en)
|
1993-01-11 |
1999-05-26 |
Dana Farber Cancer Institute |
Inducing cytotoxic t lymphocyte responses
|
|
US6224911B1
(en)
|
1993-03-16 |
2001-05-01 |
Syntex (U.S.A.) Llc |
Process for the preparation of enteric coated pharmaceutical dosage forms
|
|
WO1995003035A1
(en)
|
1993-07-23 |
1995-02-02 |
Massachusetts Institute Of Technology |
Polymerized liposomes with enhanced stability for oral delivery
|
|
GB9412394D0
(en)
|
1994-06-21 |
1994-08-10 |
Danbiosyst Uk |
Colonic drug delivery composition
|
|
AUPM873294A0
(en)
|
1994-10-12 |
1994-11-03 |
Csl Limited |
Saponin preparations and use thereof in iscoms
|
|
CA2203504A1
(en)
|
1994-10-24 |
1996-05-02 |
James A. Williams |
Vaccine and antitoxin for treatment and prevention of c. difficile disease
|
|
UA56132C2
(uk)
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
|
|
US6676935B2
(en)
|
1995-06-27 |
2004-01-13 |
Cell Genesys, Inc. |
Tissue specific adenoviral vectors
|
|
AU4133397A
(en)
|
1996-10-28 |
1998-05-22 |
Pfizer Inc. |
Oral vaccines for young animals with an enteric coating
|
|
FR2759293B1
(fr)
|
1997-02-11 |
1999-04-30 |
Ethypharm Lab Prod Ethiques |
Microgranules contenant du cisplatine, procede de fabrication, preparation pharmaceutique et utilisation en polychimiotherapie ou en association avec une radiotherapie
|
|
AUPO856097A0
(en)
|
1997-08-14 |
1997-09-04 |
Commonwealth Scientific And Industrial Research Organisation |
Vector
|
|
US6328967B1
(en)
|
1998-03-12 |
2001-12-11 |
Allergenics, Inc. |
Delivery system to modulate immune response
|
|
GB9818591D0
(en)
|
1998-08-27 |
1998-10-21 |
Danbiosyst Uk |
Pharmaceutical composition
|
|
US7264771B2
(en)
|
1999-04-20 |
2007-09-04 |
Baxter International Inc. |
Method and apparatus for manipulating pre-sterilized components in an active sterile field
|
|
US6355270B1
(en)
|
1999-01-11 |
2002-03-12 |
The Regents Of The University Of California |
Particles for oral delivery of peptides and proteins
|
|
CA2396237A1
(en)
|
2000-01-07 |
2001-07-19 |
Jacob Gabriel Michael |
Selective activation of a th1 or th2 lymphocyte regulated immune response
|
|
AU2003240978A1
(en)
|
2002-05-31 |
2003-12-19 |
Genteric, Inc. |
Multi-functional polyamines for delivery of biologically-active polynucleotides
|
|
WO2004020592A2
(en)
|
2002-08-30 |
2004-03-11 |
Genteric, Inc. |
Retroductal salivary gland genetic vaccination
|
|
GB2407500A
(en)
|
2003-11-03 |
2005-05-04 |
Ist Superiore Sanita |
Use of microparticles for antigen delivery
|
|
US20060128653A1
(en)
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of decitabine
|
|
TW200626185A
(en)
|
2004-12-17 |
2006-08-01 |
Bpsi Holdings Inc |
Enteric film coating composition containing entericpolymer micronized with detackifier
|
|
DK1996238T3
(da)
*
|
2006-02-28 |
2016-08-01 |
Vaxart Inc |
Kimæriske adenovirale vektorer og DsRNA som TLR3-agonist
|
|
DE102006060799A1
(de)
*
|
2006-12-21 |
2008-06-26 |
RUHR-UNIVERSITäT BOCHUM |
RSV F-Protein und seine Verwendung
|
|
JP2009298707A
(ja)
|
2008-06-11 |
2009-12-24 |
Ohara Yakuhin Kogyo Kk |
粒子加工方法
|
|
US20110305768A1
(en)
|
2008-07-01 |
2011-12-15 |
The Johns Hopkins University |
Quick-dissolving oral thin film for targeted delivery of therapeutic agents
|
|
CA2994066A1
(en)
|
2008-12-03 |
2010-06-10 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase c agonists and methods of use
|
|
US20120276167A1
(en)
|
2009-07-13 |
2012-11-01 |
Vaxgene Corporation |
Immunoprotection by oral administration of recombinant lactococcus lactis mini-capsules
|
|
WO2011026111A1
(en)
*
|
2009-08-31 |
2011-03-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Oral delivery of a vaccine to the large intestine to induce mucosal immunity
|
|
ES2538007T3
(es)
|
2009-09-16 |
2015-06-16 |
Vaxart, Inc. |
Estrategia de inmunización para prevenir una infección por H1N1
|
|
US20130273154A1
(en)
|
2011-03-02 |
2013-10-17 |
Joseph M. Fayad |
Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hpperlipidemia, and type 2 diabetes
|
|
CA2794196A1
(en)
*
|
2010-03-23 |
2011-09-29 |
Intrexon Corporation |
Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
|
|
AU2011276328C1
(en)
|
2010-07-06 |
2016-01-21 |
Novartis Ag |
Norovirus derived immunogenic compositions and methods
|
|
WO2012024767A1
(en)
|
2010-08-25 |
2012-03-01 |
Grant Rufus Sparling Ii |
Improved enteric active substance delivery
|
|
KR20190060879A
(ko)
|
2011-03-02 |
2019-06-03 |
제롬 쉔타그 |
단독으로 또는 c형 간염 바이러스 감염과 결합되는 간 지방증의 치료를 위한 조성물, 방법 및 진단
|
|
JP6203816B2
(ja)
|
2012-03-29 |
2017-09-27 |
セラバイオーム，エルエルシー |
回腸及び虫垂に対して活性の胃腸部位特異的経口ワクチン接種製剤
|
|
KR101867428B1
(ko)
|
2012-04-04 |
2018-07-19 |
백스폼 엘엘씨 |
경구 백신 투여용의 개선된 항원보강제 시스템
|
|
SG11201606814RA
(en)
|
2014-02-20 |
2016-09-29 |
Vaxart Inc |
Formulations for small intestinal delivery
|
|
WO2016200951A1
(en)
*
|
2015-06-12 |
2016-12-15 |
Vaxart, Inc. |
Formulations for small intestinal delivery of rsv and norovirus antigens
|